Objectives: To review clinical evidence on the antiepileptic effects of deep brain stimulation (DBS) for drug-resistant epilepsy, its safety, and the factors influencing individual outcomes. Methods: A comprehensive search of the medical literature (PubMed, Medline) was conducted to identify relevant articles investigating DBS therapy for drugresistant epilepsy. Reference lists of these articles were used to source further arti- 
of disability, with poor quality of life as well as increased morbidity and mortality. The first-line treatment for drug-resistant epilepsy is resective surgery. However, when surgery is contraindicated or ineffective, deep brain stimulation (DBS) has emerged as an important treatment option, along with other neurostimulation therapies including vagus nerve stimulation (VNS) and responsive neurostimulation (RNS).
DBS involves the delivery of a predetermined (openloop) program of electrical stimulation to deep brain structures via implanted electrodes connected to a pulse generator. Following a recent clinical trial, 3 DBS of the anterior nucleus of the thalamus (ANT) has been approved for the treatment of refractory epilepsy in Europe, Canada, and Australia. 4 DBS is also used therapeutically in movement disorders such as Parkinson's disease, essential tremor, and dystonia, and has shown potential in treating neuropsychiatric disorders such as depression and obsessive-compulsive disorder. 5 The antiepileptic effects of DBS were first studied in the 1970s and 1980s [6] [7] [8] ; however, the current evidence base remains modest, with only one large-scale randomized controlled trial (RCT) of ANT stimulation-the SANTE trial. 3 Promising although variable antiepileptic effects have been observed from smaller studies of stimulation targets including thalamic nuclei, the hippocampus, and the cerebellum. Most significantly, it remains a mystery why some patients with epilepsy respond well to DBS but others do not, and the exact mechanisms by which DBS ameliorates seizures are also poorly understood. Currently, a clinician may consider DBS for patients with drug-resistant epilepsy when reasonable attempts at antiepileptic drug therapy have failed and the patients are unsuitable for surgery. Reasons for surgical contraindication include bilateral or widespread seizure activity, proximity of ictal zone to important functional areas, and lack of anatomic abnormality on imaging. Appropriateness of DBS therapy also depends on other factors, including failure or contraindication to other neurostimulation therapies, and the lower surgical risk of electrode implantation compared with resective surgery. [9] [10] [11] Although DBS for drug-resistant epilepsy is prescribed with palliative rather than curative intent, better epileptic control may lead to improvements in quality of life, independence, and cognition. 3, 9, 12 Seizure reductions may also allow the tapering of antiepileptic drugs, thereby reducing medication side effects. [13] [14] [15] Surgical and stimulationrelated adverse effects are similar to those observed from DBS for movement disorders. 4 However, more large-scale clinical trials are needed, especially investigation of factors that might predict or improve individual patient responses to DBS. This review focuses on clinical studies that have investigated DBS in patients with drug-resistant epilepsy. Results are organized by DBS target, with emphasis on controlled clinical trials over less rigorous open-label studies. Safety data are also reviewed, followed by discussion of DBS efficacy and factors that may influence this.
| CLINICAL STUDIES ON DBS FOR DRUG-RESISTANT EPILEPSY
We identified 10 RCTs and 48 noncontrolled studies investigating DBS for drug-resistant epilepsy. Seizure outcomes from RCTs are shown in Table 1 . Study characteristics and primary outcomes are summarized in Table 2 (ANT),  Table 3 (hippocampus [HC]), Table 4 (centromedian nucleus of thalamus [CMT]), Table 5 (cerebellum), and Table S1 (other targets). Other notable observations from noncontrolled studies are listed in Table S2, and Table S3 details individual outcomes across all stimulation targets.
| Anterior nucleus of the thalamus
As part of the medial limbic (Papez) circuit, the ANT connects to the hippocampus via the mammillothalamic tract and fornix, before projecting to the cingulate cortex and neocortex. Given that this circuit is thought to be involved in emotional processing and seizure propagation, highfrequency ANT stimulation may inhibit the spread of focal seizures to cortical areas. 4, 10, 11, 16, 17 Current evidence for ANT-DBS includes one large-scale RCT 3,18 and 16 noncontrolled studies 8, 9, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] (Table 2) .
Key Points
• Long-term ANT and HC stimulation decreased seizures by 46%-90% and 48%-95% among half of all patients studied; DBS of other targets remains inconclusive
• More than 70% of patients receiving ANT or HC stimulation among existing studies are responders (experiencing a seizure reduction of at least 50%)
• Side effects and complications of DBS for drugresistant epilepsy are similar in nature to those observed from DBS therapy for other indications
• Individual responses vary markedly-potential predictors of efficacy include seizure syndrome, absence of structural abnormality, and electrode position
• More robust clinical trials are needed to investigate the determinants of efficacy and to personalize DBS therapy for patients with drug-resistant epilepsy
| Controlled clinical trials
In 2010, the landmark SANTE (Stimulation of Anterior Nucleus of Thalamus for Epilepsy) trial was published. This was a multicenter RCT in which 110 adult patients with refractory focal seizures with or without bilateral spread received DBS of the ANT. 3 After the 3-month blinded phase, seizure frequencies fell by a median of 40% in the stimulation group versus 15% for controls when compared with baseline. The stimulated group were also more likely to report subjective depression and memory impairment. Of interest, seizures were reduced by around 22% in both groups during the 1-month postimplantation prestimulation phase, perhaps reflecting a "lesional effect"-an immediate seizure reduction caused by lesioning of neural tissue from electrode implantation. 3 All participants then received unblinded DBS therapy for long-term follow-up, which revealed ongoing and progressive seizure improvement with a median seizure frequency reduction of 69% after 5 years. Sixty-eight percent of patients achieved seizure reductions of at least 50%, and there were significant improvements in seizure severity and quality of life scores across the cohort. 3, 18 Subgroup analysis showed that treatment efficacy varied with the region of seizure origin. Temporal onset epilepsies were more responsive, with a 44.2% improvement with stimulation during the blinded phase compared with 40% for the whole stimulation group. Similarly, after 5 years, patients with temporal seizure onset experienced a 76% improvement, compared with 59% for frontal epilepsies and 68% for other locations. 3, 18 The adverse effects observed in this trial will be discussed later.
| Noncontrolled studies
See Table 2 .
| Hippocampus
The hippocampus is an attractive target for DBS given its role in the Papez circuit. Hippocampal stimulation may directly attenuate (at low frequencies) or interrupt (at high frequencies) epileptic activity originating from the medial temporal region-the origin of most focal impaired awareness seizures. 4, 10, 16, 17 Thus researchers have empirically trialed HC-DBS exclusively in patients with medial temporal lobe epilepsy (MTLE), some with magnetic resonance imaging (MRI) evidence of medial temporal (hippocampal) sclerosis. Current evidence includes 4 RCTs (one trialing RNS), [34] [35] [36] [37] [38] and 9 noncontrolled studies 13, 14, [39] [40] [41] [42] [43] [44] [45] [46] [47] (Table 3) . Velasco's month-long double-blind randomized trial in 2007 on 9 refractory MTLE patients found that seizure frequencies decreased by a median of 40% in the stimulation group versus 0% in the control group (values estimated from graphs). All patients achieved seizure reductions of at least 50% during unblinded follow-up. Notably, patients with normal MRI results experienced a faster and more significant seizure decrease compared to patients with hippocampal sclerosis-99% versus 63%, respectively at 18 months. Neuropsychological outcomes trended toward improvement, with no memory decline attributed to hippocampal implantation and stimulation. 35, 36 In another double-blind, cross-over randomized trial, stimulation reduced seizures in 2 MTLE patients by an average of 33%. 37 The modest response was attributed to shorter follow-up, and selection bias (eg, preselection of patients based on positive responses to earlier trial stimulation). 41 The patient with a normal MRI result responded better than the patient with medial temporal sclerosis, supporting Velasco's earlier observations. 35, 36 However, findings from this trial are limited by its small sample size. 37 The results of these 3 RCTs 34-37 all concur that HC stimulation decreases seizures, although sample sizes were small, and there was between-study variability in the placebo effect (Table 1) . [34] [35] [36] [37] The trial with the largest sample size (N = 9)
| Controlled clinical trials
did not report values from its blinded phase directly, nor their clinical significance. 35, 36 Thus larger well-designed trials may be required to prove clinical efficacy.
It is worth noting a recent multicenter RCT (N = 191) demonstrating that RNS of seizure foci (HC or otherwise) is efficacious for refractory epilepsy. 38 
| Centromedian nucleus of the thalamus
The CMT is connected to the ascending reticular system, with wide projections to cortical regions (especially frontal), insula, and basal ganglia. CMT stimulation may desynchronize and inhibit electrical conduction through these pathways, potentially interrupting or decreasing the risk of seizure activity. 12, 22, 32, [51] [52] [53] [54] involving patients with refractory epilepsy, some of whom have Lennox-Gastaut syndrome or characteristics of LennoxGastaut syndrome-a childhood epilepsy featuring tonic and atonic seizures (Table 4) .
| Controlled clinical trials
In 1992, Fisher and colleagues published the results of a double-blind cross-over study involving 7 patients with focal and generalized epilepsy, of which 2 had LennoxGastaut syndrome. Although seizures were reduced by 30% with stimulation compared with 8% for sham stimulation, these results did not reach significance. 49 Velasco's group also found that CMT stimulation did not significantly reduce the frequency of total seizures or specific seizure types. However, electroencephalography (EEG) studies revealed a significant decrease in generalized spike-wave and secondary synchronous discharges, and focal spikes from frontal areas. Long-term unblinded stimulation was more efficacious in patients with LennoxGastaut syndrome, with an average 81.6% seizure reduction versus 57.3% for patients with primarily focal epilepsies. In addition, better outcomes were associated with radiologic and electrophysiologic confirmation of correct electrode placement on at least one side. 50 Both RCTs failed to produce evidence in support of CMT stimulation for refractory seizures, although Velasco's trial revealed better long-term responses in patients with Lennox-Gastaut syndrome. 50 
| Noncontrolled studies
See Table 4 .
| Cerebellum
Low or high-frequency stimulation of the cerebellum (CB) is thought to activate inhibitory outputs of the superomedial cerebellar cortex, regulating electrical activity within motor cortical and amygdalohippocampal regions. 16 (Table 4) .
| Controlled clinical trials
Wright's 1984 trial found that CB stimulation did not ameliorate seizures among 9 patients with quantifiable results. Although the authors note that 11 of their 12 patients thought "the trial had helped them," these subjective statements cannot be validated. 55 A more recent RCT by Velasco's group in 2005 treated 5 epileptic patients with bilateral superomedial CB-DBS. Compared to baseline, a 67% mean seizure reduction with stimulation versus 7% without stimulation was observed during the blinded period. These benefits carried over into the long-term, with a 76% reduction in generalized tonicclonic seizures, and a 57% reduction in tonic seizures. 56 Notably, the findings from these 2 RCTs are discordant, which could have several explanations. Wright's trial added some observer-recorded major seizures to patient seizure diaries, after noting that patients were less likely to record major seizures than minor seizures, and vice versa for observers. 55 Given that 3 patients were also excluded from analysis due to incomplete records or unquantifiable seizures, Wright's results may be affected by the unreliable nature of seizure records 60 -to be discussed later. Although
Velasco's trial was more stringent, using a parallel rather than cross-over protocol, the effect of selection bias cannot be excluded as there were only 5 patients (3 treated, 2 control). 56 Due to these limitations, the benefits of CB stimulation remain uncertain.
| Noncontrolled studies
See Table 5 .
| Other DBS targets
Other stimulation targets have been explored for the treatment of drug-resistant epilepsy. The subthalamic nucleus (STN) plays a critical role in motor control and modulation. Indeed, STN stimulation is used clinically in the treatment of movement disorders such as Parkinson's disease. Therefore, STN-DBS may desynchronize motor circuits, 16, 17 and has been empirically trialed in patients with motor-related seizures. 15, 21, [61] [62] [63] [64] [65] Additional targets studied include the caudate nucleus 52, 66 and nucleus accumbens (NA) 67, 68 in the basal ganglia, the posterior hypothalamus (PH), 69, 70 caudal zona incerta, 69 and fornix 71 (Table S1 ).
| Controlled clinical trials
A double-blind, cross-over trial (N = 4) found that refractory seizures were decreased by 48% during stimulation periods versus 14% during placebo periods (values derived from authors' data). However, the frequency of seizures with impaired awareness increased markedly in one individual. Neither additional nor alternative ANT stimulation improved efficacy, suggesting both ANT and NA stimulation are equally effective in some patients. Mean seizure reduction over the entire follow-up period was 23%. LG (Lennox-Gastaut syndrome).
Seizure onset: GN (generalized or not localized); F (frontal); T (temporal); C (central). DBS parameters: Alt (alternating); Cont (continuous).
Results: FU (follow-up); mo (month); SR (seizure frequency reduction); MSR (mean seizure frequency reduction); RR (responder rate (≥50% reduction)).
Other: NR (not reported); -(seizure type not present). Seizure types: GTC (primary generalized tonic-clonic); AB (absence); AT (atonic seizure/drop attack); TS (tonic seizure); MYO (myoclonic seizure); FA (focal aware-previously simple partial); FIA (focal impaired awareness-previously complex partial); FBTC (focal to bilateral tonic-clonic-previously secondarily generalized tonic-clonic).
T A B L E 5 Clinical data on CB-DBS for drug-resistant epilepsy

Seizure onset: GN (generalized or not localized); F (frontal); P (parietal); T (temporal); C (central); Uni (unilateral); Bi (bilateral). DBS parameters: Alt (alternating sides); Cont (continuous).
Results: FU (follow-up); mo (month); SF (seizure-free); SR (seizure frequency reduction); RR (responder rate (≥ 50% reduction)).
Other: NR (not reported); -(seizure type not present).
| Noncontrolled studies
See Table S1 .
| SAFETY AND ADVERSE EFFECTS
| Safety of DBS in general
The main complications of DBS can broadly be divided into 3 categories-surgical, stimulation-related, and equipment-related. Surgical complications include hemorrhage, wound infection, and implant site pain. Stimulation effects include worsening or new seizures, neurologic symptoms (eg, paresthesias and dizziness), and neuropsychological changes (eg, memory and cognitive changes). Equipmentrelated effects may include lead displacement or migration, lead fracture, erosions, and equipment infections. 16 Most DBS safety data come from patients with movement disorders such as Parkinson's disease. In one study of 728 patients receiving DBS for various movement disorders, the main surgical complications were hemorrhage (4.9%) and wound infection (1.7%). Equipment-related complications included loss of effect (2.6%), lead malposition or migration (1.7%), and hardware discomfort (1.1%). 72 Another article looked at a stratified sample of 20% of all patient discharges across the United States. Of 332 patients, they reported an overall complication rate of 6.5%, with hemorrhage or infarction in 1.2% of patients, and mechanical complications in 3.1% of patients. 73 A detailed single-center report of 319 patients reported headache (15%) and confusion (5%) as the most common postsurgical adverse events, along with stimulation-related dysarthria (4%) and cognitive disturbances (4%), and equipment-related complications such as infection (4.4%) and lead fracture (3.8%). 74 Three more articles describe similar rates of equipment-related side effects including equipment infection, electrode fracture, skin erosions, and lead migration or displacement. [75] [76] [77] Overall, DBS presents minimal rates of short and long-term complications.
| Safety of DBS for drug-resistant epilepsy
The safety of DBS for drug-resistant epilepsy is less well documented due to limited patient data. Nonetheless, similar adverse effects were observed over 5-year follow-up of the SANTE study population. 18 The most common device or stimulation-related side effects were paresthesias (22.7%), implant site pain (20.9%), and implant site infection (12.7%).
Other common complications included hardware discomfort (9.1%), ineffective product (8.2%), lead misplacement (8.2%), and sensory disturbances (8.2%). 18 Extended followup revealed no significant deterioration in cognition or depression scores. 78 It is important to note that 2 deaths due to sudden unexpected death in epilepsy (SUDEP) were reported, consistent with the expected rate in the underlying population, and 3 others died of unrelated causes. 3, 18 Of the smaller clinical trials, one reported implant site infections in 3 patients who received HC stimulation, 35, 36 and another reported an asymptomatic intracranial hemorrhage in one patient receiving CMT stimulation. 49 Across 2 small-scale trials of CB stimulation, cerebrospinal fluid (CSF) leak occurred in one, wound or equipment infections occurred in 3, and 3 patients had lead displacement requiring repositioning. 6, 55, 56 The most common complications among noncontrolled studies were intracranial hemorrhage (often asymptomatic), 23 46 for HC-DBS among noncontrolled studies spanning months to years. Indeed, a recent meta-analysis found statistically significant reductions in seizure frequency secondary to ANT-DBS (high-quality evidence) and HC-DBS (moderate-quality evidence), but not for any other targets. 79 Our pooled analysis of patients for whom individual data were available (Figure 1 ) revealed that half of all ANT-DBS patients experienced a 46%-90% decline 9, 18, 19, [21] [22] [23] [24] 26, 27, 31 in seizures, and half of all HC-DBS patients experienced a 48%-95% decrease 13, [34] [35] [36] [41] [42] [43] [44] [45] [46] [47] (interquartile ranges). Pooled responder rates (seizure reduction ≥50%) were >70% for both ANT Given that the evidence base consists primarily of openlabel studies rather than double-blind RCTs (listed in Table 1 ), there are many limitations to the discussion points raised in this article. Open-label DBS studies are exposed to confounders, investigator and patient biases when recording seizures, and the potential selection of patients more likely to respond (eg, due to seizure type, epilepsy history, or demographic factors). They also cannot distinguish between placebo effect and true treatment effect. A combination of these factors may explain why outcomes from noncontrolled studies vary substantially, and tend to be greater than controlled trials. For instance, the SANTE RCT noted a 40% decrease in seizures with ANT stimulation (versus 15% for controls), 3 compared with reductions of 53% and 80% in an open-label study of 2 patients over an equivalent 3-month period. 27 In addition, changes to stimulation parameters and antiepileptic medications were often allowed at will, potentially influencing individual responses. The most robust RCTs to date are the SANTE trial Moreover, all studies of DBS for drug-resistant epilepsy are limited by the unreliable nature of patient-recorded seizure events, known to be markedly inconsistent with events detected by an implanted seizure advisory system. 60 Therefore, our observations and conclusions should be interpreted with caution, as they are drawn from a heterogenous collection of studies, which vary in quality, patient characteristics, follow-up times, data collection, and outcome reporting. Certain seizure types and syndromes appear more amenable to stimulation of specific targets. For instance, HC stimulation has been trialed empirically for temporal epilepsies, 13, 14, [34] [35] [36] [37] [39] [40] [41] [42] [43] [44] [45] [46] [47] and CMT stimulation seems more effective for Lennox-Gastaut syndrome and in generalized seizures. 50, 54 PH stimulation may also reduce aggressive behaviors. 69, 70 Furthermore, the efficacy of DBS is comparable to other forms of neurostimulation, with an average 1-year seizure reduction of 41% for ANT-DBS versus 36% for VNS, 37% for trigeminal nerve stimulation, and 44% for RNS.
11
Many studies observed a lesional effect, that is, an immediate decrease in seizures after implantation but and RR values represent the proportion of patients achieving ≥50% seizure reduction. Values derived from individual reductions in total seizure frequency (at final follow-up) in all patients for which these data were available, across controlled and noncontrolled studies. Reliability of values are limited by open-label study design, differences in patient selection, follow-up times, data collection, and outcome reporting. before stimulation, possibly due to local tissue damage from electrode implantation. 39 The SANTE trial reported a median postimplantation seizure reduction of 22% prior to stimulation, with the control group experiencing additional improvement after initiation of unblinded stimulation. 3 However, 2 small RCTs of HC stimulation found no lesional effect. 36, 37 Simple electrode insertion also decreased seizures by 67% in one open-label study, 23 and by 32%-99% for 2-4 months in more than half the participants of another study. 33 To what extent the clinical benefits of DBS are derived from an initial lesional effect or an ongoing stimulation effect remains to be elucidated. DBS may continue to reduce seizures for up to 10 years, 25 with progressive improvements reported across the SANTE cohort-41% after 1 year, 56% after 2 years, and 69% after 5 years of DBS. 3, 18 However, there is evidence of temporal variation in response among individuals. For instance, seizure frequencies in one study were initially variable before stabilizing after 15 months of stimulation.
23
Possible reasons include differences in patient characteristics, changes to antiepileptic medications or DBS parameters during stimulation, and adverse events requiring cessation of DBS. Another question, is whether chronic DBS has any permanent effect on epileptogenesis besides network modulation. A recent study observed the effect of battery depletion in 9 patients with refractory epilepsy treated with at least 3 years of DBS. After 6 months of battery depletion, some patients' seizures returned to pre-DBS baseline levels and some experienced a partial rebound, whereas others noted no change in seizure frequency. 80 Some studies also highlighted changes in secondary outcomes. ANT stimulation reduced seizure severity and improved quality of life, but worsened subjective depression and memory impairment 3 -however, these measures may be unreliable. 29 Reduction of myoclonic seizures with STN stimulation may improve gross and fine motor skills. 64 Cognitive improvements have also been reported in ANT, CMT, and STN stimulation. 9, 15, 42 Despite the role of the hippocampus in memory processing, transient memory impairment was only observed following strong HC-DBS. 42 Neuropsychiatric symptoms and sleep arousals both decreased with nocturnal DBS voltage reduction, suggesting that cognitive side effects may be, in part, a consequence of stimulation-induced sleep disruption. 28 
| Predictors of efficacy
The antiepileptic effects of DBS vary extensively among individuals from existing studies, yet the reasons remain unknown. We attempted to identify potential factors associated with the efficacy of DBS, in the hopes of guiding further research (Table 6 ). Understanding these determinants will enable clinicians to better predict which patients will respond well, and to select the most suitable DBS target and parameters for each patient.
| Demographic factors
No studies have explicitly reported an association between stimulation efficacy and demographic characteristics such • Anterior electrode location 30, 33 • Seizures of deep temporal/temporo-frontal limbic onset. 3, 18, 29 • Normal MRI without structural abnormality.
29
• Efficacy with trial of closed-loop stimulation. • Normal MRI without hippocampal sclerosis. [35] [36] [37] • Electrodes close to subiculum, 44 or within hippocampal formation and gyrus.
39
• "Stronger" stimulation for hippocampal sclerosis.
42
CMT 2 small RCTs. 7 open-label studies.
• Electrode placement confirmed radiologically and electrophysiologically.
12,50
• Patients with Lennox-Gastaut syndrome, 50 or generalized epilepsy.
54
CB 2 small RCTs. 6 open-label studies.
• None identified.
Others 1 small RCT for NA. Open-label studies for STN (6) , PH (2), CN (2), NA (1), CZI (1), & fornix (1).
RCT, randomized controlled trial; ANT, anterior nucleus of the thalamus; HC, hippocampus; CMT, centromedian nucleus of the thalamus; CB, cerebellum; STN, subthalamic nuclei; NA, nucleus accumbens; PH, posterior hypothalamus; CN, caudate nucleus; CZI, caudal zona incerta.
as age and gender. However, inspection of individual patient data in 2 open-label studies, one of HC-DBS 47 and
another of CMT-DBS, 53 revealed an apparent relationship between younger age and greater seizure reduction. A better response in the younger of 2 patients with Dravet syndrome receiving ANT-DBS was attributed to an "aging effect," whereby a longer duration of refractory seizures may render them more resistant. 25 Conversely, some studies found no association between favorable outcome and demographic factors.
26,30
| Epilepsy history
Patient responses to DBS treatment may be influenced by features of their epilepsy history, including seizure type or onset zone, etiology, duration of epilepsy, and age at onset. There is evidence that ANT stimulation is more effective for temporal epilepsies. Subgroup analysis of the SANTE study population revealed a marginally better response in patients with temporal seizure onset (44% after 1 year, 76% after 5 years) versus the whole cohort (41% after 1 year, 69% after 5 years). 3, 18 An open-label study found that ANT stimulation was more effective for temporal or limbic-related epilepsies versus extratemporal epilepsies. Specifically, those patients with focal impaired awareness seizures of deep temporal or frontal limbic origin without anatomic abnormality on MRI (eg, dysplasia or atrophy) responded better, and those with frontotemporal ictal onset and limbic spread due to neocortical lesions responded poorer. 29 In addition, CMT stimulation is more effective in Lennox-Gastaut syndrome compared with focal onset seizures, 50 and in generalized seizures compared with frontal seizures. 54 Unilateral focal epilepsies also respond better to HC stimulation than bilateral onset epilepsies. 43 However, the investigation of HC-DBS exclusively in temporal epilepsy, and STN-DBS primarily in seizures with motor features, precludes observation of associations between response and seizure syndrome. Previous VNS or resective surgery did not affect efficacy, and patients who added medication while receiving DBS performed no different from those who did not. 3, 18 There were also no correlations between outcome and seizure-onset zone, or etiology (cortical dysplasia vs encephalitis), 30 or age at onset, or prior duration of epilepsy. 
| Investigation findings
Concerning MRI findings, follow-up from 2 small RCTs of HC stimulation revealed strong correlations between MRI normality and outcome. [35] [36] [37] In one, patients with a normal MRI (nonlesional medial temporal epilepsy) had an impressive 99% mean seizure reduction after 18 months, compared with 63% for patients with MRI evidence of medial temporal sclerosis. 35, 36 Perhaps for HC stimulation, it is worthwhile considering 2 distinct subpopulations-one with normal MRIs and the other with hippocampal sclerosiswith the hypothesis that neuronal reduction and/or electrical resistance in sclerosed neural tissue may hinder stimulation. 35, 36 In contrast, the inverse relationship was true of participants in an open-label study. 47 Patients without structural abnormality on MRI also responded better to ANT-DBS, 29 although another study found no such association. 30 The clinical utility of "evoked potentials" has been gathering interest. Evoked potentials are EEG waveforms recorded in response to a triggering electrical stimulus, such as stimulation of a deep brain structure. An early study found that low-frequency ANT stimulation (2-10 Hz) elicited a "recruiting rhythm" on EEG only in those participants who went on to achieve ≥50% seizure reduction. 19 More recently, hippocampal evoked potentials were used to confirm proper placement of ANT electrodes. 27 However, it has been argued that evoked potentials are of little localizing value, as reproducible evoked responses of variable morphology failed to correspond with correctly positioned electrodes. 24 To date, evoked potentials have been employed as a means of confirming correct electrode placement. The idea that evoked potentials might somehow predict DBS efficacy in humans with drug-resistant epilepsy is yet to be explored.
| DBS-related factors
Stimulation parameters have thus far been chosen empirically based on previous studies and investigator experience. The effects of frequency, voltage, current, pulse width, unilateral versus bilateral stimulation, and cycling versus continuous stimulation on efficacy are poorly understood.
In general, it is thought that low-frequency stimulation increases seizure risk by lowering seizure threshold and enhancing epileptogenic discharges, whereas higher frequencies desynchronize electrical activity and reduce seizure risk. 11, 16, 19 Common stimulation parameters are ≥100 Hz at 1-10 V for ANT stimulation, ≥130 Hz at 1-5 V for HC and STN stimulation, moderate to high frequency stimulation at 1-10 V for CMT stimulation, and low (10 Hz) or high (200 Hz) stimulation for the CB (Tables 2-5 ). Low frequency (4-8 Hz) high cycling ANT stimulation could also be effective. 27 Most significantly, descriptive analysis of stimulation parameters used during the long-term follow-up of the SANTE cohort found no favorable parameters in frequency, voltage, or pulse width. 3 Among noncontrolled studies, evidence suggests that hippocampal sclerosis patients may require "stronger" stimulation-either higher voltage or quadripolar stimulation-to achieve a response. 42 Yet, lowfrequency (5 Hz) HC stimulation seemed optimal in other patients with hippocampal sclerosis. 47 There were no differences between cycling and continuous stimulation, 23 and no association between output voltage and seizure reduction. 43 Comparison of unilateral to bilateral stimulation also yielded conflicting results. 43, 45 Of interest, concordance between response to closed-loop (responsive) stimulation and long-term DBS suggests that inpatient closed-loop trials may help identify optimal DBS parameters. 24 It is difficult to draw conclusions without more rigorous investigation of stimulation parameters. Positioning of DBS electrodes appears significant, as ANT-DBS electrodes located anteriorly, 30 or in the anteroventral subdivision of the ANT, 33 were correlated with a better outcome. For HC stimulation, one study found no relationship between response and distance from active electrodes to ictal focus, although good responders had active contacts <3 mm from the subiculum. 44 Another study noted that all responders to HC-DBS had electrode contacts within the hippocampal formation and the gyrus. 39 Correct electrode placement as confirmed radiologically (MRI) and electrophysiologically (EEG) was also important for CMT stimulation. 42 and correct electrode positioning. 12, 30, 33, 39, 44, 50 The limitations of these conclusions were discussed earlier.
Given the infancy of the current evidence base, more large-scale clinical trials are needed in this area. In the era of personalized medicine, the ability to tailor DBS therapy to the individual is imperative. This includes refining investigations to help select the most suitable patients, and developing a better understanding of the stimulation targets best geared toward treating specific seizure types. A range of different stimulation parameters should be explored, as innovation ought not be impeded by onerous regulations.
Of course, the accessibility of bulk data is crucialimproved data collection and aggregation will greatly assist the identification of potential factors associated with efficacy.
Novel strategies of predicting a patient's response to DBS, such as the use of evoked potentials, or inpatient trials of open-loop stimulation, should also be explored. It will be worthwhile investigating combined stimulation of multiple targets, and RNS of deep brain structures. Ongoing development of surgical implantation techniques and improvements to software and hardware will also be important.
Current indications recommend DBS only in patients with drug-resistant epilepsy unsuitable for resective surgery, but we might be missing the opportunity to modify the disease earlier in its course. Perhaps failure of drug therapy itself increases the likelihood of subsequently failing DBS therapy-a reflection of the increased treatment resistance of seizures secondary to the natural progression of epilepsy. As such, widening the indications for DBS or prescribing it earlier in the disease process may be more beneficial, targeting seizures when they are most susceptible to modulation.
Future research will hopefully sharpen the role of DBS as a valuable tool in the clinician's arsenal for tackling drug-resistant epilepsy and its debilitating consequences.
